Sarcopenia Market to See Significant Growth Through 2034, Driven by Aging Population, Diagnostic Advancements, and Emerging Therapies | DelveInsight

Sarcopenia is a progressive skeletal muscle disorder characterized by the loss of muscle mass, strength, and function. Recognized as a major contributor to frailty, falls, and physical disability in older adults, sarcopenia is increasingly drawing clinical and regulatory attention. Despite its growing clinical relevance, the condition remains underdiagnosed and often overlooked, leading to delays in intervention and management.

Currently, there are no approved pharmacological therapies specifically for sarcopenia. Standard management revolves around resistance training, nutritional support, and addressing underlying conditions. However, ongoing research is shedding light on novel therapeutic targets and biological pathways involved in muscle wasting, driving interest in drug development.

DelveInsight's comprehensive report, Sarcopenia - Market Insight, Epidemiology, and Market Forecast - 2034, offers an in-depth examination of the disease landscape across the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. It explores the evolving clinical practices, unmet needs, and the potential of emerging therapies that aim to address both primary sarcopenia and secondary forms linked to chronic conditions like cancer and liver disease.

While the sarcopenia market shows promise with several candidates in the pipeline, challenges remain in terms of clinical trial design, biomarker standardization, and regulatory pathways. Nevertheless, rising awareness, demographic trends, and technological advancements in diagnostics and muscle health monitoring are expected to drive gradual but meaningful progress in the sarcopenia treatment landscape over the coming decade.

Request a sample and uncover the latest breakthroughs shaping the sarcopenia market landscape and future outlook @ https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the Sarcopenia Market Report:
• In 2024, the sarcopenia market size in the 7MM was USD 2.2 billion, with growth expected by 2034.
• The U.S. had the highest market share, reaching USD 1.5 billion in 2025.
• Sarcopenia prevalence ranges from 18% in diabetic patients to 66% in those with unresectable esophageal cancer, and affects about 40% of individuals with liver cirrhosis.
• There were around 19.8 million diagnosed prevalent sarcopenia cases in the 7MM in 2024, projected to increase.
• In the U.S., the 65-69 age group accounted for the highest number of cases, with approximately 4.52 million in 2024.
• In January 2025, IPS HEART received Orphan Drug Designation (ODD) from the FDA for GIVI-MPCs, recognizing their potential to create new muscle with full-length dystrophin in Becker Muscular Dystrophy (BMD). The therapy has shown promising results in generating human muscle with full-length dystrophin in dystrophic pigs, young and aged Duchenne Muscular Dystrophy (DMD) mice, and a sarcopenia mouse model.
• In January 2025, TNF Pharmaceuticals announced that it had achieved a key safety data milestone supporting expanded and longer-term clinical studies of isomyosamine in multiple indications.
• In December 2024, the FDA granted Fast Track Designation to Lipocine Inc.'s LPCN 1148 for the treatment of sarcopenia in patients with decompensated cirrhosis. LPCN 1148, an oral prodrug of bioidentical testosterone, demonstrated positive results in a proof-of-concept Phase 2 study, improving sarcopenia and related clinical outcomes. The treatment aims to be a "First in Class" product with a novel mechanism for managing cirrhosis.
• In December 2024, TNF Pharmaceuticals presented positive top-line results from a Phase IIa study of its lead drug candidate MYMD-1 at a prestigious international congress of global experts in sarcopenia and related disorders.
• Emerging therapies for sarcopenia include Olpasiran MYMD-1/ Iisomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510, OC514, MT29,TRN-005, NMDP-05, PF1807, DW1030, and others.
• Key companies involved in the treatment of sarcopenia include MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Rejuvenate Biomed, Oncocross Therapeutics, OPKO Health, NMD Pharma, Rubedo Life Sciences, Immunoforge, and others.

Curious to see the graphical version of these numbers? The sarcopenia infographic is ready for you, check it out here: https://www.delveinsight.com/infographics/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Sarcopenia Overview
Sarcopenia is a progressive, age-related skeletal muscle disorder characterized by the loss of muscle mass, strength, and physical performance. Recognized as a key component of frailty syndrome, sarcopenia significantly increases the risk of falls, disability, hospitalization, and mortality, especially in elderly populations. It can also occur secondary to chronic illnesses such as cancer, chronic liver disease, heart failure, and inflammatory conditions.

The condition develops gradually, often going unnoticed until physical decline becomes apparent. Its multifactorial etiology includes hormonal changes, inflammation, malnutrition, sedentary lifestyle, and mitochondrial dysfunction. Diagnostic approaches typically involve assessing muscle strength (e.g., grip strength), muscle mass (via imaging or bioimpedance), and functional performance (such as gait speed).

Despite its widespread impact, sarcopenia has only recently gained recognition as a diagnosable disease, and pharmacological treatment options remain limited. Management strategies currently focus on resistance exercise, protein supplementation, and addressing underlying conditions. However, advancements in understanding molecular mechanisms are paving the way for novel therapies aimed at reversing or halting disease progression.

Get a free sample for the sarcopenia market forecast, size & share analysis report: https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Sarcopenia Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

Sarcopenia Epidemiology Segmentation:
The sarcopenia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Total diagnosed prevalent cases of sarcopenia
• Gender-specific diagnosed prevalent cases of sarcopenia
• Age-specific diagnosed prevalent cases of sarcopenia
• Severity -specific diagnosed prevalent cases of sarcopenia

Sarcopenia Drugs Uptake and Pipeline Development Activities
The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for sarcopenia throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the sarcopenia drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for sarcopenia, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of sarcopenia therapeutics.

Explore how emerging sarcopenia therapies are aligning with evolving patient populations @ https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Sarcopenia Market Outlook
The sarcopenia market remains largely untapped, with no approved pharmacological therapies currently available, and treatment primarily relying on nutritional support, physical activity, and lifestyle changes. As awareness of the disease grows, so does the urgency for effective therapeutic options aimed at restoring muscle mass and function.

Despite promising research, the clinical pipeline is still in its early stages, with few late-stage candidates. However, the development of potential drugs like MYMD-1, LPCN 1148, and BIO101 is generating cautious optimism. According to DelveInsight's analysis, these investigational therapies could significantly reshape the sarcopenia treatment landscape over the forecast period. The anticipated emergence of targeted therapies, along with increased focus on early diagnosis and intervention, is expected to drive the sarcopenia market growth through 2034.

Sarcopenia Market Drivers
• The rising global elderly population, most vulnerable to muscle degeneration, is a major driver accelerating the sarcopenia market. With age being the primary risk factor, the demand for effective diagnostic and therapeutic solutions is expected to rise significantly.
• Improved awareness among healthcare providers and the general public about sarcopenia symptoms, along with advancements in diagnostic tools and screening guidelines, is promoting earlier detection and intervention, boosting the market potential.

Sarcopenia Market Barriers
• Despite the high prevalence, there are currently no FDA- or EMA-approved sarcopenia drugs. The absence of standardized pharmacological treatments limits therapeutic innovation and slows commercial investment.
• Sarcopenia often goes undiagnosed or is mistaken for normal aging, especially in primary care settings. This clinical underrecognition restricts patient identification and hinders widespread adoption of future sarcopenia treatment options.

Scope of the Sarcopenia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key Sarcopenia Companies: MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Rejuvenate Biomed, Oncocross Therapeutics, OPKO Health, NMD Pharma, Rubedo Life Sciences, Immunoforge, and others.
• Key Sarcopenia Therapies: Olpasiran MYMD-1/ Iisomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510, OC514, MT29,TRN-005, NMDP-05, PF1807, DW1030, and others.
• Sarcopenia Therapeutic Assessment: Sarcopenia currently marketed, and Sarcopenia emerging therapies.
• Sarcopenia Market Dynamics: Sarcopenia market drivers and Sarcopenia market barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• Sarcopenia Unmet Needs, KOL's views, Analyst's views, Sarcopenia Market Access and Reimbursement.

To learn more about sarcopenia companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Sarcopenia Market Report Introduction
2. Executive Summary for Sarcopenia
3. SWOT analysis of Sarcopenia
4. Sarcopenia Patient Share (%) Overview at a Glance
5. Sarcopenia Market Overview at a Glance
6. Sarcopenia Disease Background and Overview
7. Sarcopenia Epidemiology and Patient Population
8. Country-Specific Patient Population of Sarcopenia
9. Sarcopenia Current Treatment and Medical Practices
10. Sarcopenia Unmet Needs
11. Sarcopenia Emerging Therapies
12. Sarcopenia Market Outlook
13. Country-Wise Sarcopenia Market Analysis (2020-2034)
14. Sarcopenia Market Access and Reimbursement of Therapies
15. Sarcopenia Market Drivers
16. Sarcopenia Market Barriers
17. Sarcopenia Appendix
18. Sarcopenia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.